产品
编 号：F761598
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 934235-44-6
产品详情
生物活性：
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.
体内研究：
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model.Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model.Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model.Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo.Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect.Animal Model:Nude mice inoculated with SK-N-FI tumor cells
Dosage:0.04 or 0.1 mg/mouse
Administration:Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days
Result:Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group.
Animal Model:Nude mice inoculated with SJSA-1 osteosarcoma
Dosage:0.02, 0.1 or 0.5 mg/mouse
Administration:Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days
Result:Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment.
Animal Model:Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells
Dosage:0.1 or 0.5 mg/mouse
Administration:Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days
Result:Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model.
Animal Model:Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma
Dosage:0.1 or 0.5 mg/mouse
Administration:Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks
Result:Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft.
Animal Model:Nude mice inoculated with SJSA-1 osteosarcoma
Dosage:0.5 mg/mouse
Administration:Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation
Result:Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1.
体外研究：
Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells.
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.
体内研究：
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model.Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model.Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model.Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo.Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect.Animal Model:Nude mice inoculated with SK-N-FI tumor cells
Dosage:0.04 or 0.1 mg/mouse
Administration:Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days
Result:Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group.
Animal Model:Nude mice inoculated with SJSA-1 osteosarcoma
Dosage:0.02, 0.1 or 0.5 mg/mouse
Administration:Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days
Result:Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment.
Animal Model:Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells
Dosage:0.1 or 0.5 mg/mouse
Administration:Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days
Result:Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model.
Animal Model:Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma
Dosage:0.1 or 0.5 mg/mouse
Administration:Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks
Result:Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft.
Animal Model:Nude mice inoculated with SJSA-1 osteosarcoma
Dosage:0.5 mg/mouse
Administration:Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation
Result:Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1.
体外研究：
Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备